A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
BeiGene
Ludwig Institute for Cancer Research
Fox Chase Cancer Center
Boston Scientific Corporation
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Radiation Therapy Oncology Group